NCT00046683 2016-07-28
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Sanofi
Phase 3 Completed
Clinical Trials
5 trialsNCT00086580 2014-03-13
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
Sanofi
Phase 3 Completed
NCT00564512 2013-07-25
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
French Innovative Leukemia Organisation
Phase 3 Completed
NCT00725231 2012-05-07
A-CHOP-14
University of Göttingen
Phase 3 Unknown
NCT00226512 2011-04-08
To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
Hadassah Medical Organization
Phase 3 Withdrawn